Actively Recruiting
Randomized, Double-Masked Trial Comparing Single Injection of 4D-150 to Aflibercept in Adults With Macular Neovascularization Due to Age-Related Macular Degeneration
Led by 4D Molecular Therapeutics · Updated on 2026-10-19
480
Participants Needed
126
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of a single intravitreal injection of 4D-150 compared to aflibercept in adults with neovascular age-related macular degeneration nAMD. This Phase 3 randomized, double-masked trial includes a primary global cohort with completed enrollment and an ongoing Japan cohort. The study aims to understand visual acuity changes and treatment needs over time in this patient population. Participants are randomly assigned to receive either one dose of 4D-150 administered as a single intravitreal injection on Day 1 or aflibercept injections at scheduled visits. The study follows participants for up to 104 weeks to assess the need for additional aflibercept injections after the initial treatment. The trial includes safety and efficacy monitoring with comparisons between the study drug and the active comparator. During the trial, participants will undergo regular eye exams including measurements of best corrected visual acuity BCVA at 52 weeks and up to 104 weeks. Central subfield thickness and other anatomical features will be monitored using imaging techniques such as fluorescein angiography and optical coherence tomography. Researchers will track injection frequency, visual function, and eye health. The total participation duration may span over two years with ongoing assessments to evaluate treatment outcomes and safety.
CONDITIONS
Brief Title
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
Research Team
4
4DMT Patient Advocacy
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here